A phase 1 clinical trial has been initiated to evaluate the safety and efficacy of BAFF ligand-based CAR-T cells in treating relapsed or refractory NHL patients, primarily focusing on MCL [79]. Here, TNFSF13B is linked to mantle cell lymphoma.